Literature DB >> 19650786

Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women.

Uğur Unlütürk1, Ayla Harmanci, Bülent Okan Yildiz, Miyase Bayraktar.   

Abstract

BACKGROUND: High molecular weight adiponectin (HMWA) is the active circulating form of adiponectin. Nampt/visfatin is the enzyme secreted from adipocytes in an active form and is one of the putative regulators of insulin secretion.
OBJECTIVE: To investigate the dynamics of total adiponectin (TA), HMWA and Nampt/visfatin in obese and lean women during oral glucose tolerance test (OGTT).
METHODS: We studied normal glucose-tolerant (NGT), age-matched, 30 obese and 30 lean women. All subjects underwent a standard 75 g, 2-h OGTT, and area under the curve (AUC) during OGTT for glucose, insulin, Nampt/visfatin, TA and HMWA was calculated. Body fat mass was assessed by bioimpedance analysis. Results Obese women had significantly higher basal and AUC values for insulin and Nampt/visfatin, whereas basal and AUC-HMWA were significantly lower in this group. Alternatively, obese and lean groups had similar basal and AUC values for glucose and TA. Basal insulin levels were negatively correlated with HMWA levels, but not with basal Nampt/visfatin. AUC-insulin was correlated positively with AUC-visfatin, and negatively with AUC-HMWA. Total and truncal body fat mass showed positive correlation with basal and AUC-visfatin, and negative correlation with basal and AUC-HMWA.
CONCLUSION: In the NGT state, obese women have higher Nampt/visfatin and lower HMWA levels, both basally and in response to oral glucose challenge. The dynamics of Nampt/visfatin and HMWA during OGTT appear to be linked with insulin and adiposity. Counter-regulatory adaptations in HMWA and Nampt/visfatin might have an impact on suggested adipoinsular axis, contributing to maintenance of normal glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650786     DOI: 10.1111/j.1365-2265.2009.03674.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  In-vitro function of upstream visfatin polymorphisms that are associated with adverse cardiometabolic parameters in obese children.

Authors:  Delicia Shu Qin Ooi; Siong Gim Ong; Chew Kiat Heng; Kah Yin Loke; Yung Seng Lee
Journal:  BMC Genomics       Date:  2016-11-25       Impact factor: 3.969

Review 2.  Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature.

Authors:  Mojtaba Bayani; Mohammad Pourali; Mohammad Keivan
Journal:  Eur J Dent       Date:  2017 Jul-Sep

3.  Extreme pathway analysis reveals the organizing rules of metabolic regulation.

Authors:  Yanping Xi; Fei Wang
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

Review 4.  Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine.

Authors:  Ambra A Grolla; Cristina Travelli; Armando A Genazzani; Jaswinder K Sethi
Journal:  Br J Pharmacol       Date:  2016-06-02       Impact factor: 8.739

5.  Visfatin induces the apoptosis of endothelial progenitor cells via the induction of pro-inflammatory mediators through the NF-κB pathway.

Authors:  Lina Sun; Shuchun Chen; Haina Gao; Luping Ren; Guangyao Song
Journal:  Int J Mol Med       Date:  2017-07-03       Impact factor: 4.101

6.  Effect of weight reduction following bariatric surgery on serum visfatin and adiponectin levels in morbidly obese subjects.

Authors:  Mohammad Javad Hosseinzadeh-Attar; Atefeh Golpaie; Leila Janani; Hoda Derakhshanian
Journal:  Obes Facts       Date:  2013-04-20       Impact factor: 3.942

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.